Satellos Bioscience Chief Scientific Officer discusses early-stage trials of the company's Duchenne muscular dystrophy drug, ...

Tracking the trajectory of symptoms may be an improvement over the traditional way of collecting patient-reported outcomes ...

The findings of a new study lend support for type 1 diabetes autoantibody screening in people with other autoimmune ...

Repurposing existing therapies may help slow muscle weakness in patients with Duchenne muscular dystrophy, a new study ...

Satellos Bioscience's experimental small-molecule drug for Duchenne muscular dystrophy is showing positive results as a stand-alone treatment, but Phil Lambert, Ph.D., the company's chief scientific ...

Phil Lambert, Ph.D., chief scientific officer of Satellos Bioscience Inc., explains the mechanism of action of the company's experimental Duchenne muscular dystrophy drug, SAT-3247, and the thinking ...